North China Pharma To Appeal $162 Million Antitrust Fine By U.S.
This article was originally published in PharmAsia News
Executive Summary
North China Pharmaceutical Group, the first Chinese pharmaceutical company to be fined for antitrust violations in the U.S., said it would appeal the $162 million fine in a federal court.